摘要: 代谢功能障碍相关脂肪性肝病(MASLD)与现代生活方式密切相关,本文综述了饮食、运动、睡眠及心理因素四个方面对MASLD的影响。西方膳食模式增加患病风险,而地中海饮食和咖啡摄入具有保护作用;久坐是独立危险因素,有氧与力量训练可直接改善肝脏脂肪变性,且不依赖于体质量下降;睡眠时长与MASLD风险呈U形关系,阻塞性睡眠呼吸暂停综合征和昼夜节律失调加剧肝损伤;慢性心理压力与MASLD互相影响形成恶性循环。单一维度干预效果有限,整合的多学科综合管理策略,是实现肝脏代谢和整体健康系统性改善的最根本手段。
刘毓骁, 朱传龙. 生活方式影响代谢功能障碍相关脂肪性肝病的研究现况[J]. 肝脏, 2026, 31(6): 919-922.
| [1] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2023, 78(6): 1966-1986. [2] Loomba R, Wong V W. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease[J]. Aliment Pharmacol Ther, 2024, 59(2): 150-156. [3] Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. [4] Wong V W, Chan W K, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part 1: definition, risk factors and assessment[J]. J Gastroenterol Hepatol, 2018, 33(1): 70-85. [5] Chen M J, Chen Y, Lin J Q, et al. Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease[J]. Front Nutr, 2025, 11:1421386. [6] Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(6): 1470-1478. [7] Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development[J]. Nutrients, 2021, 13(5): 1442. [8] He J, Wang Y, Weng F. Fast food consumption and risk of non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Front Public Health, 2025, 13:1600826. [9] Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms[J]. Liver Int, 2017, 37(7): 936-949. [10] Riazi K, Raman M, Taylor L, et al. Dietary patterns and components in nonalcoholic fatty liver disease (NAFLD): what key messages can health care providers offer?[J]. Nutrients, 2019, 11(12): 2878. [11] Bjermo H, Iggman D, Kullberg J, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial[J]. Am J Clin Nutr, 2012, 95(5): 1003-1012. [12] Moore J B, Gunn P J, Fielding B A. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease[J]. Nutrients, 2014, 6(12): 5679-5703. [13] Xia Y, Wu Q, Dai H, et al. Associations of nutritional, lifestyle, and metabolic factors with non-alcoholic fatty liver disease: an umbrella review with more than 380 000 participants[J]. Front Nutr, 2021, 8:642509. [14] Asgari-Taee F, Zerafati-Shoae N, Dehghani M, et al. Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Eur J Nutr, 2019, 58(5): 1759-1769. [15] Zhang X, Ruan J, He Y, et al. Dietary inflammatory index and the risks of non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Front Nutr, 2024, 11:1388557. [16] Chen J, Zhou H, Jin H, et al. Role of inflammatory factors in mediating the effect of lipids on nonalcoholic fatty liver disease: a two-step, multivariable mendelian randomization study[J]. Nutrients, 2022, 14(20): 4434. [17] Harrison S A, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis[J]. Am J Gastroenterol, 2003, 98(11): 2485-2490. [18] Valibeygi A, Davoodi A, Dehghan A, et al. Dietary inflammatory index (DII) is correlated with the incidence of non-alcoholic fatty liver disease (NAFLD): fasa PERSIAN cohort study[J]. BMC Nutr,2023,9:84. [19] Doustmohammadian A, Clark C C T, Maadi M, et al. Favorable association between mediterranean diet (MeD) and DASH with NAFLD among Iranian adults of the amol cohort study (AmolCS)[J]. Sci Rep,2022,12(1): 2131. [20] Ebadi M, Ip S, Bhanji R A, et al. Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: systematic review with meta-analysis of observational studies[J]. Nutrients, 2021, 13(9): 3042. [21] Sewter R, Heaney S, Patterson A. Coffee consumption and the progression of NAFLD: a systematic review[J]. Nutrients, 2021, 13(7): 2381. [22] Coelho M, Patarrāo R S, Sousa-Lima I, et al. Increased intake of both caffeine and non-caffeine coffee components is associated with reduced NAFLD severity in subjects with type 2 diabetes[J]. Nutrients, 2022, 15(1): 4. [23] Hsu S J, Lee F Y, Wang S S, et al. Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats[J]. Hepatology, 2015, 61(5): 1672-1684. [24] Ma Q, Ye J, Shao C, et al. Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials[J]. Ther Adv Endocrinol Metab, 2022, 13:20420188221122426. [25] Petersen A M W, Pedersen B K. The anti-inflammatory effect of exercise[J]. Journal of applied physiology, 2005, 98(4): 1154-1162. [26] Słomko J, Zalewska M, Niemiro W, et al. Evidence-based aerobic exercise training in metabolic-associated fatty liver disease: systematic review with meta-analysis[J]. J Clin Med, 2021, 10(8): 1659. [27] Babu A F, Csader S, Lok J, et al. Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: a systematic review and meta-analysis[J]. Nutrients, 2021, 13(9): 3135. [28] Yang H J, Hong Y P, Yoon T Y, et al. Independent and synergistic associations of aerobic physical activity and resistance exercise with nonalcoholic fatty liver disease[J]. Gut Liver, 2023, 17(4): 600-609. [29] Whitsett M, VanWagner L B. Physical activity as a treatment of non-alcoholic fatty liver disease: a systematic review[J]. World journal of hepatology, 2015, 7(16): 2041. [30] Hallsworth K, Adams L A. Lifestyle modification in NAFLD/NASH: facts and figures[J]. JHEP Rep, 2019, 1(6): 468-479. [31] Lara-Romero C, Romero-Gómez M. Treatment options and continuity of care in metabolic-associated fatty liver disease: a multidisciplinary approach[J]. Eur Cardiol, 2024, 19:e06. [32] Keating S E, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from Exercise and Sport Science Australia[J]. Sports Med, 2023, 53(12): 2347-2371. [33] Yang J, Zhang K, Xi Z, et al. Short sleep duration and the risk of nonalcoholic fatty liver disease/metabolic associated fatty liver disease: a systematic review and meta-analysis[J]. Sleep Breath, 2023, 27(5): 1985-1996. [34] Zhang F, Xue Y, Li W. Exploring the impact of sleep duration and sleep disorders on metabolic dysfunction-associated steatotic liver disease in older adults[J]. BMC Geriatr, 2025,25(1): 61. [35] Umbro I, Fabiani V, Fabiani M, et al. Association between non-alcoholic fatty liver disease and obstructive sleep apnea[J]. World J Gastroenterol, 2020, 26(20): 2669-2681. [36] Zong G, Mao W, Wen M, et al. Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults[J]. Ann Hepatol, 2024, 30(2): 101583. [37] Xiao J, Lim L K E, Ng C H, et al. Is fatty liver associated with depression? A meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease[J]. Front Med (Lausanne), 2021, 8:691696. [38] Shea S, Lionis C, Kite C, et al. Non-alcoholic fatty liver disease (NAFLD) and potential links to depression, anxiety, and chronic stress[J]. Biomedicines, 2021, 9(11): 1697. [39] Zhang S, Ma C, Wang X, et al. Impact of chronic psychological stress on nonalcoholic fatty liver disease[J]. Int J Clin Exp Med, 2019, 12: 7991-7998. [40] Hänsel A, Hong S, Cámara R J, von Känel R. Inflammation as a psychophysiological biomarker in chronic psychosocial stress[J]. Neurosci Biobehav Rev,2010,35(1): 115-121. [41] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6): 1388-1402. [42] Lomonaco R, Sunny N E, Bril F, et al. Nonalcoholic fatty liver disease: current issues and novel treatment approaches[J]. Drugs,2013,73(1): 1-14. [43] Kenneally S, Sier J H, Moore J B. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review[J]. BMJ Open Gastroenterol, 2017, 4(1): e000139. |
| [1] | 任昱霖, 宋雨泽, 娄子璇, 杨涛, 温晓玉. RAS抑制剂在代谢功能障碍相关脂肪性肝病管理中的价值研究进展[J]. 肝脏, 2026, 31(5): 606-609. |
| [2] | 朱坤, 刘牧云. 儿童代谢功能障碍相关脂肪性肝病的疾病负担与远期结局[J]. 肝脏, 2026, 31(5): 609-615. |
| [3] | 周靖媛, 周嘉, 柳涛, 高沿航. 酒精性肝病相关肝细胞癌与其他病因所致肝细胞癌的差异[J]. 肝脏, 2025, 30(8): 1028-1032. |
| [4] | 庄启程, 杨长青. 拉尼兰诺治疗代谢功能障碍相关脂肪性肝炎的机制与临床研究进展[J]. 肝脏, 2025, 30(8): 1036-1038. |
| [5] | 刘爱芳, 罗磊, 杨文龙. 国内外代谢相关脂肪性肝病管理指南中生活方式干预对比[J]. 肝脏, 2025, 30(7): 1012-1016. |
| [6] | 路子瑶, 杨松. 酒精性肝病命名的中西方差异[J]. 肝脏, 2025, 30(5): 584-587. |
| [7] | 陈慧洁, 彭舟, 张琴. 祛脂方调控ITGB6/IL23A/STAT3信号通路改善MASH相关肝纤维化[J]. 肝脏, 2025, 30(5): 675-682. |
| [8] | 余虹, 郭峰, 笪欣. 影像学及机器学习在代谢功能障碍相关脂肪性肝病中的应用价值[J]. 肝脏, 2025, 30(11): 1577-1579. |
| [9] | 黄震霆, 徐小萍, 吴静. 从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的命名讨论[J]. 肝脏, 2024, 29(8): 900-904. |
| [10] | 袁乙富, 杜晟楠, 何诗嘉, 曹勤, 华红梅, 蒋元烨. 生活方式对瘦型非酒精性脂肪性肝病患者的影响[J]. 肝脏, 2024, 29(8): 980-984. |
| [11] | 钱晓婧, 陈颖, 刘王振祖, 张家祺, 蒋元烨, 胡诚. 等热量低碳水化合物高蛋白饮食对非酒精性脂肪性肝病血清脂质的影响[J]. 肝脏, 2024, 29(6): 706-713. |
| [12] | 徐衍, 饶慧瑛. 从非酒精性脂肪性肝病到代谢相关脂肪性肝病的变迁[J]. 肝脏, 2024, 29(3): 255-257. |
| [13] | 刘百怡, 饶慧瑛. 非酒精性脂肪性肝病更名及其影响[J]. 肝脏, 2023, 28(9): 1012-1014. |
| [14] | 万明月, 王晓琳, 徐玉敏, 谢青. 慢性乙型肝炎合并代谢性疾病罹患肝细胞癌的风险分析[J]. 肝脏, 2023, 28(10): 1238-1241. |
| [15] | 钱怡婷, 杨文卓. 生活方式干预防治非酒精性脂肪性肝病的现状[J]. 肝脏, 2022, 27(7): 822-825. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||